
Photo: Depositphotos
Aug 18, 2025, 16:46
How Do We Select the Best 2L Therapy for Advanced EGFR‑Mutant NSCLC After Osimertinib? – Oncogene Cancer Research
Oncogene Cancer Research shared a post on X:
“How do we select the best 2L therapy for advanced EGFR‑mutant NSCLC after osimertinib?
Dr. Julia Rotow outlines options by resistance mechanism, including the emerging amivantamab + lazertinib combo. Personalized strategies matter.”
More posts featuring Oncogene Cancer Research.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 18, 2025, 16:37
Aug 18, 2025, 16:33
Aug 18, 2025, 16:25
Aug 18, 2025, 16:10
Aug 18, 2025, 15:59
Aug 18, 2025, 15:58